Market Place
Sourcing Support
NPS Pharma`s Parathyroid Hormone Receives Supplemental Approval in US
07 Apr 2022 //
FDA
NPS Pharm`s Natpara (Parathyroid Hormone) Receives Approval in US
10 Jun 2020 //
FDA
Shire CEO Ornskov racks up $21M in pay, a fivefold leap from 2014
31 Mar 2016 //
FIERCE PHARMA
With Baxalta in hand, Shire`s not looking to buy. But sell? Maybe
11 Feb 2016 //
FIERCE PHARMA
Pharma M&A shoots up to $159B for first half, but prices could dampen the mood
17 Jul 2015 //
FIERCE PHARMA
What’s Real in Rare Disease
18 Apr 2015 //
PHARM EXEC.COM
Careful, European drugmakers. Fitch says M&A may be a bit too heated
17 Apr 2015 //
FIERCE PHARMA
Shire`s Lialda, Gattex are hedge funder`s latest patent targets
07 Apr 2015 //
FIERCE PHARMA
RARE Alert: Shire Said To Be Weighing
28 Mar 2015 //
BETAVILLE
Shire`s Shopping Spree Continues With A $245M Deal To Buy PhIII-Ready Meritage
24 Feb 2015 //
FIERCE BIOTECH
Pharma`s Top 10 M&A Deals of 2014
18 Feb 2015 //
FIERCE PHARMA
NPS Pharm`s Natpara (Parathyroid Hormone) Approved in USA for Hypoparathyroidism
23 Jan 2015 //
NPS PHARMS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.